Showing 3991-4000 of 10630 results for "".
Take 5
https://practicaldermatology.com/columns/take-5/0408_pd-take-5-pdf/22705/Take 5The First 5 Minutes with a Patient
https://practicaldermatology.com/series/pa-perspectives/first-5-minutes-patient/27105/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses the importance of crafting the right message during the first 5 minutes with a patient.The Emergence of Targeted Therapies for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.DERM2020 Exhibitor Reaction: Brett Fair, EPI Health
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-exhibitor-reaction-brett-fair-epi-health/19847/Brett Fair of EPI Health, a DERM2020 exhibitor, tells us what he thinks of the new virtual meeting world and how DEF is dominating it for dermatology!FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuCOVID-19 Impact: iPledge and Isotretinoin Prescribing
https://practicaldermatology.com/topics/acne-rosacea/covid-19-impact-ipledge-and-isotretinoin-prescribing/19763/For patients on isotretinoin, complying with the iPledge program while treating patients virtually can be challenging. Joshua Zeichner, MD discusses new FDA guidance that allows female patients to take OTC pregnancy tests in order to continue treatment. He also discusses when patients do and do notPractical Dermatology March 2026: Page-Turner Format
https://practicaldermatology.com/issues/march-2026/practical-dermatology-march-2026-page-turner-format/56412/Patient Perspectives on Unmet Needs in Topical Psoriasis Therapy
https://practicaldermatology.com/issues/january-february-2025/patient-perspectives-on-unmet-needs-in-topical-psoriasis-therapy/32972/Despite the advantages of topical treatment, nonadherence (including overuse and underuse) affects up to 50% of patients, and therapy overuse is often incited by the desire for rapid clearance, ineffectiveness, and unclear instructions.Eyes Have It: Bloodless Blephs and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/eyes-have-it-bloodless-blephs-and-more/18728/Demand for treatments around the eye continue to grow; patients want big results but little downtime. Dr. Niamtu discusses his "bloodless bleph" and other uses for fillers and toxins.COVID-19 Impact: Virtual Care for Young Patients
https://practicaldermatology.com/topics/practice-management/covid-19-impact-virtual-care-for-young-patients/19765/With most dermatology practices closing their doors during the COVID-19 pandemic, telemedicine is emerging as an effective option for patient care. Peter Lio, MD offers tips for overcoming technology difficulties and enhancing communication during teleconsults. He also offers insights into how he is